WuXi Biologics
About WuXi Biologics
WuXi Biologics is a global biologics contract development and manufacturing organization (CDMO) offering end-to-end solutions from discovery through commercial manufacturing. The company specializes in mammalian and microbial production platforms, CMC development, analytical sciences, and regulatory support to accelerate biologics programs from concept to commercialization. With capabilities spanning antibody discovery, protein production and engineering, process development, characterization, biosafety testing, and large-scale manufacturing, WuXi Biologics serves biopharma companies worldwide. Its operations cover multiple facilities across regions to support clinical and commercial biologics manufacturing.
Recent News
Stock Trader’s Guide to Navigating High Stakes Trump-Xi Talks
The Top 10 PharmTech Videos of 2025
Sinorda and WuXi Partner on Bispecific Antibody Development and Manufacturing
15 Companies You’ll See at NIBRT Careers in Biopharma 2026
What Are some of the Top Biopharmas Looking for in a Job Applicant?
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
HanchorBio and WuXi Biologics Form Fusion Protein Pipeline Partnership
Recent Deals
No recent deals for this company.